Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
1.660
+0.040 (2.47%)
At close: Apr 17, 2026, 4:00 PM EDT
1.820
+0.160 (9.64%)
After-hours: Apr 17, 2026, 7:52 PM EDT
Innate Pharma Stock Forecast
Stock Price Forecast
The 4 analysts that cover Innate Pharma stock have a consensus rating of "Strong Buy" and an average price target of $5.75, which forecasts a 246.39% increase in the stock price over the next year. The lowest target is $2.00 and the highest is $8.00.
Price Target: $5.75 (+246.39%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Innate Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +201.20% | Apr 7, 2026 |
| BTIG | BTIG | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +381.93% | Mar 12, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold → Strong Buy Upgrades $5 | Hold → Strong Buy | Upgrades | $5 | +201.20% | Oct 29, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +381.93% | Oct 29, 2025 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $10 → $2 | Buy → Hold | Downgrades | $10 → $2 | +20.48% | Sep 18, 2025 |
Financial Forecast
Revenue This Year
25.25M
from 9.01M
Increased by 180.36%
Revenue Next Year
15.70M
from 25.25M
Decreased by -37.81%
EPS This Year
-0.48
from -0.55
EPS Next Year
-0.97
from -0.48
Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 57.1M | 18.7M | |||
| Avg | 25.2M | 15.7M | |||
| Low | 5.9M | 13.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 534.3% | -26.0% | |||
| Avg | 180.4% | -37.8% | |||
| Low | -34.8% | -48.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.43 | -1.01 | |
| Avg | -0.48 | -0.97 | |
| Low | -0.59 | -0.94 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.